The latest report by IMARC Group, titled" Single-Use Bioreactors Market Report by Product Type (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Others), Type (Stirred-tank Bioreactors, Wave-induced Bioreactors, Bubble-column Bioreactors, and Others), Cell Type (Mammalian Cell, Bacteria, Yeast, and Others), Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins, and Others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes, and Others), and Region 2024-2032", offers a comprehensive analysis of the industry, which comprises insights on the market. The global single-use bioreactors market size reached US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.1 Billion by 2032, exhibiting a growth rate (CAGR) of 13.8% during 2024-2032.

 

Factors Affecting the Growth of the Global Single-Use Bioreactor Industry:

 

  • Reduced Risk of Contamination: 

Another significant factor propelling the growth of the single-use bioreactor market is the reduced risk of contamination. Traditional bioreactors require rigorous cleaning and sterilization protocols to prevent cross-contamination between batches, which can be both time-consuming and prone to human error. Single-use bioreactors, in contrast, utilize pre-sterilized, disposable bags and components that are used for a single production cycle and then discarded. This approach virtually eliminates the risk of cross-contamination, ensuring higher product purity and quality. The reduced contamination risk is particularly critical in the production of biologics, vaccines, and other high-value pharmaceuticals where maintaining sterility and consistency is paramount.

 

  • Cost Efficiency and Stability: 

Another factor driving the single-use bioreactor market is the cost efficiency and scalability these systems offer. Single-use bioreactors reduce the need for costly and time-consuming cleaning and sterilization processes associated with traditional stainless-steel bioreactors. This reduction in overhead decreases labor and resource costs and shortens the turnaround time between production batches. As a result, manufacturers can achieve higher productivity and flexibility, crucial for meeting the demands of a dynamic market. Additionally, single-use systems are particularly advantageous for small to mid-sized biopharmaceutical companies, which may not have the capital to invest in large-scale stainless-steel facilities.

 

  • Flexibility and Speed in Bioprocess Development: 

Flexibility and speed in bioprocess development are crucial factors driving the adoption of single-use bioreactors. In the fast-paced biopharmaceutical industry, the ability to quickly adapt to changing production requirements and accelerate the development of new therapies is essential. Single-use bioreactors offer unparalleled flexibility, as they can be easily configured and scaled according to the specific needs of different production stages, from research and development to full-scale manufacturing. This adaptability allows biopharmaceutical companies to swiftly respond to market demands and technological advancements. Moreover, the faster setup times associated with single-use systems facilitate rapid process development and optimization, significantly reducing the time required to bring new drugs to market.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/single-use-bioreactor-market/requestsample

 

Leading Companies Operating in the Global Single-Use Bioreactor Market

  • ABEC Inc.
  • Cellexus
  • Celltainer Biotech B.V.
  • CESCO Bioengineering Co. Ltd.
  • Distek Inc.
  • Eppendorf SE
  • General Electric Company
  • Getinge AB
  • Merck KGaA
  • Pall Corporation (Danaher Corporation)
  • PBS Biotech Inc.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.

Single-Use Bioreactor Market Report Segmentation:

 

By Product Type:

 

  • Single-use Bioreactor Systems
  • Media Bags
  • Filtration Assemblies
  • Others

Single-use bioreactor systems account for the largest market share as they are meant for single time usage, which eliminates the need of the vigorous cleaning and sterilization procedure. 

 

By Type:

 

  • Stirred-tank Bioreactors
  • Wave-induced Bioreactors
  • Bubble-column Bioreactors
  • Others

Stirred tank bioreactors dominates the market due to their efficiency, scalability, and versatility in a wide variety of bioprocessing applications. 

 

By Cell Type:

 

  • Mammalian Cell
  • Bacteria
  • Yeast
  • Others

Mammalian cell represents the leading segment as they are critical for producing complex biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and vaccines.

 

By Molecule Type:

 

  • Vaccines
  • Monoclonal Antibodies
  • Stem Cells
  • Recombinant Proteins
  • Others

Vaccines dominate the market due to the rising global demand for vaccines, driven by the continuous upsurge of infectious diseases. 

 

By End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Others

Pharmaceutical and biopharmaceutical companies dominate the market as they leverage single-use systems to produce a wide range of therapeutics, including monoclonal antibodies, recombinant proteins, and, notably, vaccines.

 

Regional Insights:

 

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

 

North America’s dominance in the single-use bioreactor market is attributed to robust biopharmaceutical industry with significant investment in research and development.

 

Global Single-Use Bioreactor Market Trends:

Innovations in single-use technologies, such as improved sensor integration, automation, and scalability, are enhancing the efficiency and reliability of SUBs. These advancements are making single-use systems more attractive for various stages of bioprocessing. Besides, the growth of personalized medicine, including cell and gene therapies, is boosting the demand for flexible and scalable bioprocessing solutions. SUBs are ideal for small-scale, high-mix production environments required for personalized treatments. Moreover, regulatory agencies are increasingly recognizing the benefits of single-use systems, leading to more favorable regulatory environments. This support is encouraging broader adoption of SUBs across the industry.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

 

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

 

IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.

 

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

 

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145